CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN)
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
The most frequent genetic mutation in BCR-ABL1-negative myeloproliferative neoplasm (MPN), essential thrombocythemia (ET), and primary myelofibrosis (PMF) is the JAK2V617F mutation, which is present in approximately 50% to 60% of patients. It serves as a confirmatory molecular marker of these diseases. Mutations in the MPL gene are found in an additional 5% to 10% of ET and PMF cases. It was recently discovered that somatic mutation (insertions and/or deletions) in exon 9 of the CALR gene is the second most frequent somatic mutation after JAK2 in ET and PMF patients, and it is mutually exclusive of JAK2 and MPL mutations.(1,2) It has a frequency of approximately 49% to 88% in JAK2 and MPL-wild type (WT) ET and PMF, and is not found in polycythemia vera (PV) patients.(1-4) Therefore, CALR mutation serves as an important diagnostic molecular marker in ET and PMF.
The CALR gene encodes for calreticulin, a multifunctional protein with a C-terminus rich in acidic amino acids and a KDEL ER-retention motif. All the pathologic CALR mutations reported to date are out-of-frame insertion and/or deletions (indel) in exon 9, generating a 1 base-pair (bp) frame shift and a mutant protein with a novel C-terminus rich in basic amino acids and loss of the KDEL ER-retention signal. The most common mutation types are 52-bp deletion (c.1092_1143del, L367fs*46) and 5-bp insertion (c.1154_1155insTTGCC, K385fs*47), and they comprise approximately 85% of CALR mutations in MPN.(1,2) CALR mutations have been found in hematopoietic stem and progenitor cells in MPN patients(2) and may activate the STAT5 signaling pathway.(1) They are associated with decreased risk of thrombosis in ET (1,3-5), and better survival in PMF compared to JAK2 mutations.(5)
Rapid and sensitive detection of insertion and deletion-type mutations in exon 9 of CALR
An aid in distinction between reactive thrombocytosis and/or leukocytosis versus a myeloproliferative neoplasm (MPN), especially essential thrombocythemia (ET) and primary myelofibrosis (PMF), and is highly informative in cases in which JAK2 and MPL testing are negative
Especially helpful to the pathologist in those bone marrow cases with ambiguous etiology of thrombocytosis, equivocal bone marrow morphologic findings of MPN, and/or unexplained reticulin fibrosis
An aid in prognostication of PMF and thrombosis risk assessment in ET.
An interpretive report will be issued.
The results will be reported as 1 of the 3 states if DNA amplification is successful (see Cautions):
-Positive. A deletion/insertion-type mutation was detected in CALR, exon 9.
-Negative. No deletion or insertion was detected in CALR, exon 9.
-Equivocal. A small amplicon suspicious for a deletion/insertion type mutation was detected in CALR, exon 9.
Positive mutation status is highly suggestive of a myeloid neoplasm, but must be correlated with clinical and other laboratory and morphologic features for definitive diagnosis.
Negative mutation status does not exclude the presence of a myeloproliferative neoplasm or other neoplastic disorders.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
A positive result is not specific for a particular myeloproliferative neoplasm (MPN) diagnosis and clinicopathologic correlation is necessary in all cases.
A negative result does not exclude the presence of a MPN or other neoplastic process.
This test is a fragment analysis assay, and only detects insertions and deletions (indels). It will not detect point mutations. However, all reported pathologic mutations in MPN described to date are insertions and/or deletions.
This test may not differentiate between out-of-frame and in-frame indels in rare cases. However, in-frame indel mutations are very rare (<0.5%), and have only been reported in few healthy individuals and myeloproliferative neoplasm patients with JAK2V617F mutation or out-of-frame CALR mutation. Most of the rare in-frame indels are considered germline mutations and represent non-pathogenic polymorphisms.
Infrequently, amplification failure can be encountered in a given sample, due to inadequate DNA, poor DNA quality, or a PCR inhibitor. In these circumstances, the assay will be reattempted and if persistently unsuccessful, the report will be issued with an "Invalid" result.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
An interpretive report will be provided
Clinical References Provides recommendations for further in-depth reading of a clinical nature
2. Nangalia J, Massie CE, Baxter EJ, et al: Somatic CALR mutation in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405
3. Rumi E, Pietra D, Ferretti V, et al: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Published online before print December 23, 2013
4. Rotunno G, Mannarelli C, Guglielmelli P, et al: Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552-1555
5. Tefferi A, Lasho TL, Finke CM, et al: CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia advance online publication 21 January 2014